153 related articles for article (PubMed ID: 26759984)
21. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
22. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF.
Woodward RM; Brown ML; Stewart ST; Cronin KA; Cutler DM
Cancer; 2007 Dec; 110(11):2511-8. PubMed ID: 17955504
[TBL] [Abstract][Full Text] [Related]
23. Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century.
Pulte D; Redaniel MT; Bird J; Jeffreys M
Eur J Haematol; 2015 Jun; 94(6):540-5. PubMed ID: 25315799
[TBL] [Abstract][Full Text] [Related]
24. Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.
Danese MD; Reyes CM; Gleeson ML; Halperin M; Skettino SL; Mikhael J
Med Care; 2016 Apr; 54(4):343-9. PubMed ID: 26759977
[TBL] [Abstract][Full Text] [Related]
25. Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
Ohm L; Lundqvist A; Dickman P; Höglund M; Persson U; Stenke L; Carlsson KS; Björkholm M
Leuk Lymphoma; 2015 May; 56(5):1385-91. PubMed ID: 25139694
[TBL] [Abstract][Full Text] [Related]
26. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Lairson DR; Parikh RC; Cormier JN; Du XL
Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
[TBL] [Abstract][Full Text] [Related]
28. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
Skrepnek GH; Ballard EE
Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
[TBL] [Abstract][Full Text] [Related]
29. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Ito K; Elkin E; Blinder V; Keating N; Choudhry N
Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
[TBL] [Abstract][Full Text] [Related]
31. Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications.
Shen C; Zhao B; Liu L; Shih YT
J Oncol Pract; 2017 Feb; 13(2):e152-e162. PubMed ID: 28095170
[TBL] [Abstract][Full Text] [Related]
32. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
33. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.
Bower H; Björkholm M; Dickman PW; Höglund M; Lambert PC; Andersson TM
J Clin Oncol; 2016 Aug; 34(24):2851-7. PubMed ID: 27325849
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
Poonawalla IB; Lairson DR; Chan W; Piller LB; Du XL
Value Health; 2015 Jun; 18(4):387-95. PubMed ID: 26091592
[TBL] [Abstract][Full Text] [Related]
35. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.
Lee SJ; Kuntz KM; Horowitz MM; McGlave PB; Goldman JM; Sobocinski KA; Hegland J; Kollman C; Parsons SK; Weinstein MC; Weeks JC; Antin JH
Ann Intern Med; 1997 Dec; 127(12):1080-8. PubMed ID: 9412310
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
[TBL] [Abstract][Full Text] [Related]
37. The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
Ector GICG; Govers TM; Westerweel PE; Grutters JPC; Blijlevens NMA
Leuk Lymphoma; 2019 Jun; 60(6):1485-1492. PubMed ID: 30668187
[TBL] [Abstract][Full Text] [Related]
38. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
Griffiths RI; Gleeson ML; Danese MD; O'Hagan A
Value Health; 2012; 15(5):656-63. PubMed ID: 22867774
[TBL] [Abstract][Full Text] [Related]
39. Trends in leukemia incidence and survival in the United States (1973-1998).
Xie Y; Davies SM; Xiang Y; Robison LL; Ross JA
Cancer; 2003 May; 97(9):2229-35. PubMed ID: 12712476
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B).
Reynolds MR; Magnuson EA; Wang K; Lei Y; Vilain K; Walczak J; Kodali SK; Lasala JM; O'Neill WW; Davidson CJ; Smith CR; Leon MB; Cohen DJ;
Circulation; 2012 Mar; 125(9):1102-9. PubMed ID: 22308299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]